Search
Pretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigationalPersistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target p...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSQ-109
go.drugbank.com/drugs/DB05186InvestigationalSQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesBezisterim
go.drugbank.com/drugs/DB05212InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesHepatitis B immune globulin
go.drugbank.com/drugs/DB05276ApprovedInvestigationalLong-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. ...
Products: HEPATITIS B IMMUNOGLOBULIN P BEHRING, HEPATITIS B IMMUNOGLOBULIN P BEHRING 1000 IU/5 ML IM KULLANIMA HAZIR ENJEKTÖRDE ENJEKSİYONLUK ÇÖZELTİVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsPimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalPimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPalovarotene
go.drugbank.com/drugs/DB05467ApprovedFibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which res...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersTelaprevir
go.drugbank.com/drugs/DB05521ApprovedWithdrawnTelaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesApremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigationalApremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesStaurosporine
go.drugbank.com/drugs/DB02010ExperimentalAn indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)
Categories: P-glycoprotein inhibitors